Pharmaceutical company gifts: From voluntary standards to legal demands

Hastings Center Report

Volumn 36, Issue 3, 2006, Pages 8-9

  Dresser, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; EVIDENCE BASED MEDICINE; GIFT GIVING; GOVERNMENT; HUMAN; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; MEDICAL ETHICS; MEDICAL STUDENT; PHARMACIST; PHYSICIAN; SHORT SURVEY; STANDARD; UNITED STATES;

ADVERTISING; CODES OF ETHICS; CONFLICT OF INTEREST; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; GIFT GIVING; HUMANS; PHARMACISTS; PHYSICIANS; STUDENTS, MEDICAL; TRUTH DISCLOSURE; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;

EID: 33745912246     PISSN: 00930334     EISSN: None     Source Type: Journal    
DOI: 10.1353/hcr.2006.0039     Document Type: Short Survey

References (14)

1. Department of Health and Human Services Office of Inspector General, OIG Compliance Program Guidance for Pharmaceutical Manufacturers, Federal Register 68 (2003): 23, 731-43.
2. Calif. Health and Safety Code sec. 119400-02 (2005), at http://wwww.leginfo.ca.gov.
3. Vt. Stat. Ann. tit. 33, sec. 2005 (2004), at http://www.atg.state.vt.us.
4. A. Robeznieks, "More States Consider Laws for Reporting Industry Gifts," American Medical News, May 9, 2005.
5. Public Citizen, "Public Citizen Files Suit to Obtain Information Gathered under Vermont's Pharmaceutical Marketing Disclosure Law," August 29, 2005, at http://www.citizen.org.
6. J. Dana and G. Loewenstein, "A Social Science Perspective on Gifts to Physicians from Industry," Journal of the American Medical Association 290 (2003): 252-55.
7. D. Blumenthal, "Doctors and Drug Companies," New England Journal of Medicine 351 (2004): 1885-90.
8. Pharmaceutical Research and Manufacturers of America, "Code on Interactions with Health Professionals," 2002, at http://www.phrma.org/ publications/policy/2004-01-19.391.pdf.
9. American Medical Association, "Ethical Opinions and Guidelines," updated 2005, http://www.ama-assn.org/ama/pub/ category/print/4001.html.
10. T. Brennan et al., "Health Industry Practices That Create Conflicts of Interest," Journal of the American Medical Association 295 (2006): 429-33.
11. J. Avorn, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (New York: Knopf, 2004), 338.
12. American Medical Student Association, "Towards a PharmFree Profession," April 28, 2005, at http://www.amsa.org/prof/history. cfm.
13. F. Sierles et al., "Medical Students' Exposure to and Attitudes about Drug Company Interactions," Journal of the American Medical Association 294 (2005): 1034-42.
14. D. Studdert, M. Mello, and T. Brennan, "Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry-Self-Regulation in the Shadow of Federal Prosecution," New England Journal of Medicine 351 (2004): 1891-1900.